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PMH24
IMPROVEMENT OF FATIGUE IN PATIENTS WITH MAJOR
DEPRESSIVE DISORDER TREATED WITH VENLAFAXINE,
SERTRALINE, OR PLACEBO
Zhang HF, Khandker R
Wyeth Research, Collegeville, PA, USA
OBJECTIVE: This analysis was designed to compare improve-
ment in symptoms of fatigue in depressed patients treated 
with venlafaxine extended release (XR), sertraline, or placebo.
METHODS: Data were pooled from two identical ten-week,
multicenter, randomized, double-blind, placebo-controlled
studies of ﬂexible-dose venlafaxine XR (37.5–300mg/day) and
sertraline (50–200mg/day) in the treatment of DSM-IV major
depressive disorder (N = 1352). The Hamilton Rating Scale for
Depression scale (HAM-D) energy subscale (sum of items one,
seven, eight, and 14) and the Montgomery-Asberg Depression
Rating Scale (MADRS) lassitude item were used to assess fatigue
symptoms. Improvement was measured as reduction from base-
line score at week ten using ANCOVA method controlling for
center and baseline values. Overall trend of weekly scores during
treatment was measured using repeated measures mixed model.
The last-observation-carried-forward (LOCF) approach was
used to handle missing data. RESULTS: On the MADRS lassi-
tude item venlafaxine XR was associated with signiﬁcantly
greater reduction from baseline (P < 0.0001) and signiﬁcantly
better weekly trend (P < 0.0001) versus placebo. Venlafaxine XR
was also associated with signiﬁcantly greater reduction from
baseline on the HAM-D energy subscale (P = 0.0007) and better
overall weekly trend (P = 0.0003) relative to placebo. Sertra-
line/placebo differences were also statistically signiﬁcant. 
CONCLUSION: Venlafaxine XR and sertraline treatment were
associated with signiﬁcant improvement in fatigue symptoms in
depressed patients based on two independent measures.
PMH25
COST AND UTILIZATION DIFFERENCES AMONG CARDIAC
PATIENTS TREATED FOR DEPRESSION WITH ZOLOFT
VERSUS NO PHARMACEUTICAL TREATMENT
Bron MS1, Mark TL2, Orsini LS3
1Pﬁzer, New York, NY, USA; 2Medstat, Washington, DC, USA;
3MedStat, Inc, Cambridge, MA, USA
OBJECTIVE: To determine the differences in health care expen-
ditures among patients hospitalized with acute myocardial
infarction or unstable angina that were subsequently treated for
depression associated with their cardiac event with either ser-
taline or no antidepressant therapy. METHODS: Patients 45 or
older, 12 months of continuous enrollment, evidence of pre-
scription drug claims, a hospitalization for either acute myocar-
dial infarction (ICD-9-CM code 411.1x) or unstable angina
(410.00–410.92) and evidence of depression treatment (diagno-
sis or pharmaceutical) were identiﬁed in Medstat’s MarketScan
Databases. Claims incurred between January 1, 1999 and
December 31, 2003 were utilized. Patients without any antide-
pressant use 30 days prior or 60 days after their cardiac event
and receiving a diagnosis of depression in the 180 days before
or after their cardiac event comprised the diagnosis only group.
Patients with a 30 day clean period of any antidepressant prior
to their cardiac event and incurring a script for sertaline (but no
other antidepressant) in the 60 days after their cardiac event
comprised the sertaline group. Patients in the two groups were
matched using propensity score methods. RESULTS: A total 
of 257 patients in each group were identiﬁed. The mean total
per person expenditure for acute MI admission was signiﬁcantly
higher for diagnosis only patients ($3184) versus sertaline
patients ($1063) p = 0.0098. The mean total per person expen-
diture for psychiatric related outpatient visits was also higher in
the diagnosis only group: $326 versus $69 p < 0.0001. There
were no other signiﬁcant differences in expenditures. CON-
CLUSION: Patients treated for depression after a hospitalization
for a major coronary event who receive sertaline have fewer AMI
admissions and costs for AMI admissions as well as fewer psy-
chiatric related outpatient visits and related costs in the 24 weeks
following their initial cardiac event.
PMH26
COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE
TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TURKEY
Hemels ME1, Karamustafal oglu O2, Ozmen E3, Dilsad S4, Mene S3
1H. Lundbeck A/S, Paris, Ile de France, France; 2Etfal Hospital, Istanbul,
Sisli,Turkey; 3Lundbeck Ìlaç Ticaret Limited, Istanbul, Ìlaç,Turkey;
4Marmara University, Istanbul,Turkey
OBJECTIVES: To compare the cost-effectiveness of escitalopram
with generic citalopram and venlafaxine in the treatment of
Major Depressive Disorder (MDD) in Turkey. METHODS: A
decision analytic model with a six-month horizon was adapted
to the Turkish setting. All patients (aged ≥ 18 years) were treated
by a psychiatrist over a period of six months. Model inputs
included drug-speciﬁc probabilities from head-to-head trial data,
literature, and expert opinion. A national survey was conducted
among psychiatrists (n = 90; response rate = 96.7%) to obtain
patterns of clinical management, resource utilization and lost
productivity data (all weighted by practice size). The main
outcome measure was success [i.e., remission deﬁned as Mont-
gomery-Åsberg Depression Rating Scale (MADRS) score £12]
and costs (in US$ 2004) of treatment (i.e., costs of drugs and
medical care). The analysis was performed from the govern-
mental and societal perspectives. Human capital approach was
used to estimate the cost of lost productivity using the minimal
industrial wage in Turkey. RESULTS: Treatment with escitalo-
pram yielded lower expected costs and greater effectiveness com-
pared with citalopram. The expected success rate was higher for
escitalopram [63.2% (CI95 61.1%–65.3%)] compared with
generic citalopram [57.6% (CI95 55.3%–59.9%)]. From the
governmental perspective, total expected costs were US$297
(US$282–US$313) for escitalopram and US$305 (US$288–
US$322) for generic citalopram. From the societal perspective
the costs per patient were US$678 (US$653–US$705) for esci-
talopram and US$709 (US$682–US$736) for generic citalopram.
For venlafaxine, a similar success rate compared with escitalo-
pram but higher total costs were found from both the govern-
mental (i.e., 23.5%) and societal (i.e., 9.3%) perspectives.
Multivariate sensitivity analyses on unit costs and probabilities
demonstrated the robustness of the results. CONCLUSION:
Escitalopram is a cost-effective alternative compared to (generic)
citalopram and a cost saving alternative compared with ven-
lafaxine in the treatment of MDD in Turkey.
PMH27
COST-EFFECTIVENESS OF ESCITALOPRAM VS. VENLAFAXIN
XR IN THE TREATMENT OF MAJOR DEPRESSIVE 
DISORDER IN GERMANY
Kulp W1, Greiner W2, Schulenburg JM3
1University of Hannover, Hannover, Germany; 2University of
Hannover, Hannover, Germany; 3University of Hannover, Hannover,
Germany
OBJECTIVE: The treatment of Major Depressive Disorder
(MDD) represents a substantial ﬁnancial burden to modern
health care systems. The 12-month prevalence is estimated to be
12% in adult patients. Selective serotoninreuptake-inhibitors
(SSRI) such as Escitalopram and Venlafaxin XR play an impor-
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tant role in treating that disorder in primary care. We demon-
strate the cost-effectiveness of Escitalopram for Germany 
measured by successfully treated patients. METHODS: A
markov-model over a horizon of 70 days with three markov-
stages (remission, partial response, no response) was con-
structed. Due to the fact that the perspective of the physician was
taken, only costs for medication have been considered. In order
to include therapeutic decisions of physicians in a naturalistic
matter, a survey of 190 GPs and 60 specialists has been 
conducted. RESULTS: Escitalopram has a 30% (GP: 113 vs. 144
€/successfully treated patient, specialist: 123 vs. 163 €/success-
fully treated patient) more favourable cost-effectiveness ratio
compared with Venlafaxin XR. Depending on the setting (GP/
Specialist) the incremental cost-effectiveness ratio is considered
to be 6800–7400€. The lower costs in the GPs model are due to
referrals to specialists, since from the GPs perspective no further
costs occur. CONCLUSIONS: Escitalopram is a cost-effective
alternative to Venlafaxin XR for the treatment of MDD in the
German setting.
PMH28
A COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM 
AND SERTRALINE IN THE TREATMENT OF MAJOR
DEPRESSIVE DISORDER
Armstrong EP1, Skrepnek GH1, Malone DC1, Erder H2
1University of Arizona College of Pharmacy,Tucson, AZ, USA; 2Forest
Research Institute, Jersey City, NJ, USA
OBJECTIVE: To compare the cost-effectiveness of escitalopram
and sertraline for the treatment of depression based upon a head-
to-head clinical study and published literature. METHODS: A
decision analytical model was created based upon data obtained
from an eight-week clinical study evaluating escitalopram 
and sertraline for the treatment of major depressive disorder. 
The primary outcome of the clinical study was improvement in
depressive symptoms as measured by the Montgomery-Asberg
Depression Rating Scale. The model was constructed from a
payer’s perspective with a six-month time horizon. The clinical
trial allowed dose titration for sertraline in 50mg increments.
The primary outcome for the model was cost per quality-
adjusted life year (QALY). The decision analysis took into
account the rate of adverse drug reactions by drug and dose.
QALY estimates were assigned to various health states and
included depression, adverse events, and treatment failure. Med-
ication costs were obtained from an Internet pharmacy. Costs of
adverse events and treatment failure were obtained from pub-
lished studies. Estimated physician costs were obtained from US
Medicare fee schedules. RESULTS: The estimated six-month cost
was $952 for escitalopram and $1372 for sertraline. The 
estimated QALYs were 0.403 for escitalopram and 0.393 for 
sertraline. The cost/QALY for the two agents was $2362 and
$3494, respectively. Threshold analyses were conducted to deter-
mine variables that inﬂuenced the results. The most important
variable in the model was the cost of treatment failures. In the
primary analysis, the cost of treatment failures was $8141. When
this cost was reduced to $5000, the cost/QALY was $1993 and
$2808 for escitalopram and sertraline, respectively. CONCLU-
SIONS: The results suggest that escitalopram had a lower cost
and resulted in more QALYs. This difference was due mainly to
a lower ADR rates for escitalopram and fewer titrations with
escitalopram.
PMH29
THE EFFECT OF RAISING THREE TIER COPAYMENTS ON SSRI
COMPLIANCE RATES
Bron MS1, Mark TL2
1Pﬁzer, New York, NY, USA; 2Medstat, Washington, DC, USA
OBJECTIVES: 1) To characterize design of drug beneﬁts of SSRI
antidepressants in health plans offered by employers in the
United States; and 2) To determine the effect of raising copay-
ments on compliance rates of SSRI antidepressants. METHODS:
Data comprised beneﬁt information and claims from Medstat’s
MarketScan database for 2000–2003. Beneﬁt information were
compiled from approximately 135 different plans. Any patient
who ﬁlled a prescription SSRI antidepressants in 2000 and was
continuously enrolled through 2001 was identiﬁed. A difference
in difference approach was used to examine the change in the
days supplied and number of claims ﬁlled for an employer that
raised their three tiered co-payments as compared to an employer
that kept constant one tier copayment rates. RESULTS: Three
tier copayment structures were increasingly common among
employers. Most SSRIs fall in tier two although some of the
newer SSRIs are commonly found in tier three. The average
copayment for tier 1 increased from $5.40 to $7.40. The average
copayment for tier 2 increased from $13.60 to $16.80. The
average copayment for tier 3 increased from $25.40 to $31.20.
When the study employer raised their co-payments by 50%, they
experienced a 25% decline in the number of prescriptions per
person ﬁlled (from 5.2 to 3.9 prescriptions) from 2000 to 2001,
while the control employer demonstrated a 20% decline (from
6.0 to 4.8) in the number of prescriptions ﬁlled. Days supplied
fell by 41.3 days or 24% in the employer that raised copayments
and by 36.3 days or 17% in the control employer. CONCLU-
SIONS: Beneﬁt structure and co-pays have trended towards 
3-tier plans with increasing copayments. As such, increasing
copayments may have a negative effect on compliance and 
possibly outcomes.
PMH30
OUTCOME ANALYSIS OF A MULTI-LEVEL INTERVENTION
PROGRAM TO IMPROVE ANTIDEPRESSANT 
MEDICATION ADHERENCE
Alison L1,Wong SL2
1Healthﬁrst, New York, NY, USA; 2Pﬁzer Inc, Syosset, NY, USA
Despite the importance of medication adherence in the manage-
ment of depression, adherence rates for antidepressant therapy
are poor. Failure to adhere to pharmaceutical therapy leads to
poor clinical outcomes and increased health care costs. OBJEC-
TIVE: To evaluate the impact of an interventional program on
antidepressant medication adherence. METHODS: This was a
prospective interventional program with retrospective adherence
study using 24-month pharmacy claims database. Medication
adherence measures included length of therapy, median gap, per-
sistence over time, and procession ratio were obtained prior to
and at 18 months post implementation of interventions. Physi-
cian educational interventions included on-site provider educa-
tion, review of The Agency for Healthcare Research and Quality
(AHRQ) guidelines for major depression, newsletter, and case
management. Patient interventions included case managers fol-
lowed up with non-compliant patients by phone for oral coun-
seling, newsletter, incentive programs, and reminder postcards.
RESULTS: A total of 4021 patients were included in the study.
Signiﬁcant improvements were observed at post intervention for
all adherence parameters. The average length of therapy at
outcome measure was 165 days compared to 131 days at base-
line. Persistence over time showed 72% of patients completed
their acute phase therapy (84 days) compared to 60% at base-
line (p < 0.001) and 55% of patients continued their continua-
tion therapy (180 days) compared to 46% at baseline (p <
0.001). The procession ratio over time at 180 days was 0.8, an
improvement of 24% from the baseline. CONCLUSIONS:
Results of our analysis indicated signiﬁcant improvements in
